Skip to main content
Equibles
VSBC logo

VSBC · Vitaspring Biomedical Co. Ltd.

Track VSBC — free

Use VSBC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VSBC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.03 At close · Oct 8
Rebalance outlook locked
Going-concern doubt — flagged Sep 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has concluded that its plans, which depend on obtaining financing that is not within the Company's control, cannot be considered probable of being effectively implemented and therefore do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Sep 17, 2026
Market Cap
$6.58M
Shares
207.03M
Volume · Oct 8 100 Avg daily vol (1 sessions) 100

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.03 Open$0.03 Day$0.03–0.03 Available close range$0.01–0.03 Avg vol 30d1K Short int50 · 0.0% float Short vol50% DataFeb 2020–Oct 2026 Filing10-Q · Sep 17

The closing range uses available history since Feb 12, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Sep 17, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$455,643
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$13,367
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −100%
below
RSI (14) 19
oversold
MACD trend Negative
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −100%
trailing
YTD return −97%
this year
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 831%
annualized · 1-yr
Max drawdown −100%
past year
ATR 4923.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−100% Bearish
RSI (14)
19 Neutral
MACD trend
Negative Bearish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its available closing range
Range low $0 Now $0 · 100% Range high $0
vs 50-day avg -100%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VSBC
Vitaspring Biomedical Co. Ltd.
this stock
$6.58M — — — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
50
Days to cover
1000.0d
Change
0 sh
View
Short Volume
Short vol %
50%
As of
Aug 11, 2023
Short Total
View
Fails to Deliver
FTD shares
42
Value
$638
As of
Mar 23, 2023
View
Off-Exchange
Off-exchange %
100.0%
Week of
Feb 9, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-415.4K
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
10-Q
Filed
Sep 17, 2026
This year
15
View

Performance

5D 20D 120D MTD YTD
VSBC -82.3% -99.8% — +186.5% -96.8%
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY -83.6% -101.9% — +185.0% -110.3%
Key facts CIK 1697884 Visit website